![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Progression of the FIB-4 Index among
Patients with Chronic HCV Infection
|
|
|
AASLD 2020 Nov 11-16
Reported by Jules Levin
Lisette A.P. Krassenburg1,2, RaoelMaan1, Amy Puenpatom3, Nicole Erler4, Christoph Welsch5, Stijn van Hees6, Orlando Cerrhoci2, Johannes Vermehren5, Robert J. de Knegt1,
Bettina E. Hansen2,7 , Stefan Zeuzem5, Thomas Vanwolleghem6, Harry L.A. Janssen2, Robert A. de Man1, Jordan J. Feld2, Adriaan J. van der Meer1
1. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands; 2. Toronto Centre for Liver Disease, Toronto General Hospital, University Health Network, Toronto,Canada; 3. Center for Observational and Real-World Evidence (CORE), Merck & Co., Inc., Kenilworth, NJ, USA;
4. Department of Biostatistics, Erasmus MC University Medical Center, Rotterdam, the Netherlands; 5. MedizinischeKlinik1, Klinikumder Johann Wolfgang Goethe-Universität, Frankfurt amMain, Germany; 6. Departmentof GastroenterologyandHepatology, University HospitalAntwerp, Antwerp, Belgium;
7. Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada.
![1130201](../images/112820/112820-4/1130201.gif)
![1130202](../images/112820/112820-4/1130202.gif)
![1130203](../images/112820/112820-4/1130203.gif)
![1130204](../images/112820/112820-4/1130204.gif)
![1130205](../images/112820/112820-4/1130205.gif)
![1130206](../images/112820/112820-4/1130206.gif)
![1130207](../images/112820/112820-4/1130207.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|